← Back to Research Papers

Medical analogies help to grasp the logic behind behaviour change interventions.

Authors: Crutzen R, Peters GJ
Journal: Annals of medicine
mental health psychology open access

Abstract

Osteoarthritis (OA) is the most common joint disease in dogs and a leading cause of chronic pain, impaired mobility, and reduced quality of life []. Pain is a hallmark clinical feature of canine OA. However, its assessment remains challenging in routine veterinary practice, because pain-related behaviors and functional limitations are often subtle, variable, and not fully observable during clinical examinations alone []. Consequently, relying solely on veterinarian-based assessments may underestimate the true impact of OA-associated pain in affected dogs []. To address these limitations, clinical metrology instruments (CMIs), particularly owner-reported outcome measures, have become essential for assessing and monitoring chronic pain and functional impairment of dogs with OA []. CMIs capture multidimensional aspects of pain and function in the home environment, providing clinically meaningful information that complements physical examination findings. The Canine Brief Pain Inventory (CBPI) is one of the most widely used owner-reported outcome measures for assessing pain associated with canine OA []. As the long-term management of canine OA increasingly relies on sustained analgesic therapy and owner-based monitoring, availability of a validated Korean-language CMI is important for accurate pain assessment and outcome monitoring []. The CBPI consists of two related domains: Pain Severity Score (PSS) comprising four items that assess pain intensity and a Pain Interference Score (PIS) comprising six items that evaluate the impact of pain on daily activities and functional performance. All items were scored on a 0–10 numerical rating scale, with higher scores indicating worse pain or greater functional interference. In addition, the CBPI includes a single global quality-of-life (QOL) item []. This has been extensively adopted in clinical practice and major randomized clinical trials of OA therapeutics as an owner-reported outcome measure for canine OA [].